Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.83 |
| ▸ | FAP | Q12884 | 6/20 | 0.71 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.71 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.71 |
| ▸ | GHSR | Q92847 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576288 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL14935777 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637493 | 1.00 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3969508 | 0.94 | DPP4 (0.80) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL638362 | 0.94 | DPP4 (0.83) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637386 | 0.94 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL16391894 | 0.94 | DPP4 (0.73) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL637743 | 0.93 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL3548101 | 0.93 | DPP4 (0.73) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL636842 | 0.93 | DPP4 (0.81) | DPP4FAPPOU2F2ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879011-B2 | Amorphous form of linagliptin and process for preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2018-01-30 | — | — | US | claimed |
| US-9108964-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| US-20150051228-A1 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2015-02-19 | — | — | US | claimed |
| US-20140128604-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | US | claimed |
| CN-114527200-B | Detection method of linagliptin related substances | 成都倍特药业股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-110590780-B | Preparation method of medicine linagliptin for treating diabetes | 深圳市第二人民医院 | 2020-10-09 | — | — | CN | disclosed |
| CN-111574520-A | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-111574463-A | Riagliptin intermediate compound IV | 鲁南制药集团股份有限公司 | 2020-08-25 | — | — | CN | disclosed |
| WO-2020031040-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BOC-LINAGLIPTIN | RICHTER GEDEON NYRT. (HU) | 2020-02-13 | — | — | WO | disclosed |
| CN-110590780-A | Preparation method of medicine linagliptin for treating diabetes | 深圳市第二人民医院 | 2019-12-20 | — | — | CN | disclosed |
| US-20120208831-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120165525-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DIPHARMA FRANCIS S.R.L. (IT) | 2012-06-28 | — | — | US | disclosed |
| US-8178541-B2 | For therapy of type I and type 11 diabetes mellitus, arthritis, obesity, or calcitonin-induced osteoporosis, allograft transplantation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8119648-B2 | Arthritis, obesity, (non-insulin dependent) diabetes calcitonin-induced osteoporosis; administering allograft transplantation; dipeptidyl peptidase-IV (DPP-IV) inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165525-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DPP4, DPP8, DPP7 | DPP4 1/4885FAP 82/4885POU2F2 3669/4885 |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 12/4885POU2F2 2892/4885 |
| US-20150051228-A1 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF | DPP4, PYGL, GID4 | DPP4 1/4885FAP 134/4885POU2F2 4164/4885 |
| US-20120208831-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 15/4885POU2F2 2763/4885 |
| US-20140128604-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 15/4885POU2F2 2763/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 12/4885POU2F2 2892/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 21/4885POU2F2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.